Charles Packshaw joins us to head up our Board of Trustees after a 30-year career in the City of London. He tells us why the appointment means so much to him personally and how he intends to break his PB at his next cycling fundraiser for us.
BLOG: It's been 12 months since we launched our ambitious plan to halve prostate cancer deaths in a decade, and we’ve already taken some huge steps towards our goal. Our chief executive, Angela Culhane, reflects on the progress we’ve made and the exciting work still to come.
We welcome today's reports of a new test by scientists at the University of East Anglia to determine whether a prostate cancer is aggressive or not, but the tell-tale pattern of 45 specific genes hasn't yet been proven to work for all men.
Boxer David Haye, Chuka Umunna MP and Olympic medallist Linford Christie are among the black celebrities leading the charge in a major new awareness drive by Prostate Cancer UK to alert black men about their increased risk of the most common cancer in men.
BLOG: We're only 12 months into our ten-year strategy to tame prostate cancer, but that doesn't mean we haven't already made exciting progress. Our resident expert, Dr Ian Le Guillou, gives us his top ten biggest research breakthroughs (in no particular order) from 2016.
With the support of the Movember Foundation, we're funding four PhD students in the crucial field of bioinformatics, using big data to help accelerate our understanding and treatment of prostate cancer.
From stem cells to bacterial infections, our £2.6 million Research Innovation Awards will fund eight potentially game-changing research projects into our understanding and treatment of prostate cancer to help us meet our ambitious aim of taming the disease within a decade.
BLOG: In the fourth part of her series on our new strategy, Sophie Lutter explains why support for today is as much a priority as planning for tomorrow.
BLOG: In the third part of her blog about our ambitious plan to tame prostate cancer in ten years, Sophie Lutter outlines the reasons behind our prevention strategy.
BLOG: In the second part of her blog about our new strategy, Sophie Lutter discusses what we'll be doing on clinical trials and advanced prostate cancer.